Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASKG915 in advanced solid tumors
NCT05867420Phase 2Recruiting
- Sponsor
- AskGene Pharma
- Start
- Aug 2023
- Primary completion
- Dec 2026
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Therapeutic Vaccines
- Countries
- 2
01
Overview
Phase 2, open-label trial of ASKG915 in solid tumor (advanced stage) (4 arms), sponsored by AskGene Pharma. Primary endpoints: Dose Limiting Toxicities at 28 days and Adverse Events. Started Aug 2023; status: recruiting.
02
Drugs
ASKG915
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05867420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05867420.